Capricor Therapeutics Inc. Reports Q1 2026 Financial Results and Announces Corporate Updates
Capricor Therapeutics Inc. (NASDAQ: CPCR) released its first‑quarter 2026 financial results on May 12, 2026, following a detailed earnings call transcript posted by Benzinga. The company, which focuses on biological therapies for Duchenne muscular dystrophy (DMD) and other rare disorders, disclosed a GAAP earnings per share (EPS) of –$0.59, a miss of $0.06 compared with analyst expectations of –$0.53. The loss per share represents a slight deterioration from the previous year’s –$0.53.
Financial Highlights
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| GAAP EPS | –$0.59 | –$0.53 |
| Net Loss | Not specified in the provided sources | Not specified |
| Revenue | $0.0 million (unchanged from Q1 2025) | $0.0 million |
| Analyst Consensus | –$0.53 EPS | –$0.53 EPS |
The company’s revenue for the quarter remained flat at zero, consistent with the prior year, while analyst expectations for the fiscal year 2026 EPS average around –$0.10, a modest improvement from the –$2.26 loss reported in 2025. Forecasted annual revenue for 2026 is projected at $122.8 million, up from $0.0 million in 2025.
Corporate Update
During the earnings call, Capricor’s management highlighted progress on its lead clinical program, deramiocel, a therapeutic product aimed at treating DMD. The company announced a PDUFA (Priority Review Voucher) date of August 22, 2026, signaling a target for FDA review by that date. Management also disclosed plans to scale manufacturing capacity to accommodate 2,000 to 2,500 patients per year once the product is approved.
Market Reaction and Analyst Commentary
The day after the earnings release, the stock traded at $31.52 (close on May 11, 2026). Analysts from B.Riley maintained a price target of $63 based on FDA progress, reflecting optimism about the company’s pipeline despite the current quarterly loss. The company’s market capitalization stood at $1.85 billion at the time of reporting.
Summary
Capricor Therapeutics Inc. continues to advance its DMD therapy pipeline, with a scheduled FDA review in August 2026 and a planned expansion of manufacturing capacity. While Q1 2026 results show a small decline in GAAP EPS and flat revenue, the company’s strategic milestones and positive analyst sentiment suggest a focus on long‑term growth rather than immediate profitability.
